



Kent Academic Repository

Benfield, Camilla, Smith, Sarah E., Wright, Edward, Wash, Rachael S., Ferrara, Francesca, Temperton, Nigel J. and Kellam, Paul (2015) *Bat and pig Interferon-Induced Transmembrane Protein 3 restrict cell entry by influenza virus and lyssaviruses*. *Journal of General Virology*, 96 (5). ISSN 0022-1317.

Downloaded from

<https://kar.kent.ac.uk/46718/> The University of Kent's Academic Repository KAR

The version of record is available from

<https://doi.org/10.1099/vir.0.000058>

This document version

Author's Accepted Manuscript

DOI for this version

Licence for this version

UNSPECIFIED

Additional information

Versions of research works

Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal*, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries

If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

Journal of General Virology

Bat and pig Interferon-Induced Transmembrane Protein 3 restrict cell entry by influenza virus and lyssaviruses --Manuscript Draft--

Manuscript Number:	JGV-D-14-00286R2
Full Title:	Bat and pig Interferon-Induced Transmembrane Protein 3 restrict cell entry by influenza virus and lyssaviruses
Short Title:	Bat and pig IFITM3 restrict zoonotic viruses
Article Type:	Standard
Section/Category:	Animal - Negative-strand RNA Viruses
Corresponding Author:	Camilla Benfield Royal Veterinary College Hatfield, UNITED KINGDOM
First Author:	Camilla Benfield
Order of Authors:	Camilla Benfield Sarah E. Smith Edward Wright Rachel S. Wash Francesca Ferrara Nigel J. Temperton Paul Kellam
Abstract:	<p>Interferon-induced transmembrane protein 3 (IFITM3) is a restriction factor which blocks cytosolic entry of numerous viruses that utilise acidic endosomal entry pathways. In humans and mice, IFITM3 limits influenza-induced morbidity and mortality. Although many IFITM3-sensitive viruses are zoonotic, whether IFITMs function as antiviral restriction factors in mammalian species other than humans and mice is unknown. Here, IFITM3 orthologues in the microbat <i>Myotis myotis</i> and the pig (<i>Sus scrofa domestica</i>) were identified using rapid amplification of cDNA ends. Amino acid residues known to be important for IFITM3 function were conserved in the pig and bat orthologues. Ectopically-expressed pig and microbat IFITM3 co-localised with transferrin (early endosomes) and CD63 (late endosomes/multivesicular bodies) and trafficked from the plasma membrane into endosomes following live cell staining. Pig and microbat IFITM3 restricted cell entry mediated by multiple influenza HA subtypes and lyssavirus G proteins. Expression of pig or microbat IFITM3 in A549 cells reduced influenza virus yields and nucleoprotein expression. Conversely siRNA knockdown of IFITM3 in pig NPTr cells and primary microbat cells enhanced virus replication, demonstrating that these genes are functional in their species of origin at endogenous levels. In sum, we show that IFITMs function as potent broad-spectrum antiviral effectors in two mammals - pigs and bats - identified as major reservoirs for emerging viruses.</p>

1 **Bat and pig Interferon-Induced Transmembrane Protein 3 restrict cell entry by**
2 **influenza virus and lyssaviruses**

3

4

5 Camilla T. O. Benfield^{1#}, Sarah E. Smith², Edward Wright⁴, Rachael S. Wash², Francesca
6 Ferrara⁵, Nigel J. Temperton⁵ and Paul Kellam^{2,3}

7

8 ¹Department of Pathology and Pathogen Biology, The Royal Veterinary College, Hatfield,
9 UK; ²Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
10 Cambridge, UK; ³ MRC/UCL Centre for Medical Molecular Virology, Division of Infection and
11 Immunity, University College London, London, UK; ⁴ Viral Pseudotype Unit (Fitzrovia),
12 Faculty of Science and Technology, University of Westminster, London, UK; ⁵ Viral
13 Pseudotype Unit (Medway), School of Pharmacy, University of Kent, Chatham Maritime,
14 Kent, UK

15

16

17 Running Title: Bat and pig IFITM3 restrict zoonotic viruses

18

19 # Address correspondence to Camilla Benfield, cbenfield@rvc.ac.uk, Tel: +44 (0)1707

20 667059, Fax: +44 (0)1707 652090

21

22 Contents category: Standard paper

23

24 Summary: 198 words

25 Text: 5500 words

26 Figures: 8

27

28 **Summary**

29

30 Interferon-induced transmembrane protein 3 (IFITM3) is a restriction factor which blocks
31 cytosolic entry of numerous viruses that utilise acidic endosomal entry pathways. In humans
32 and mice, IFITM3 limits influenza-induced morbidity and mortality. Although many IFITM3-
33 sensitive viruses are zoonotic, whether IFITMs function as antiviral restriction factors in
34 mammalian species other than humans and mice is unknown. Here, IFITM3 orthologues in
35 the microbat *Myotis myotis* and the pig (*Sus scrofa domesticus*) were identified using rapid
36 amplification of cDNA ends. Amino acid residues known to be important for IFITM3 function
37 were conserved in the pig and bat orthologues. Ectopically-expressed pig and microbat
38 IFITM3 co-localised with transferrin (early endosomes) and CD63 (late
39 endosomes/multivesicular bodies). Pig and microbat IFITM3 restricted cell entry mediated by
40 multiple influenza HA subtypes and lyssavirus G proteins. Expression of pig or microbat
41 IFITM3 in A549 cells reduced influenza virus yields and nucleoprotein expression.
42 Conversely siRNA knockdown of IFITM3 in pig NPTr cells and primary microbat cells
43 enhanced virus replication, demonstrating that these genes are functional in their species of
44 origin at endogenous levels. In sum, we show that IFITMs function as potent broad-spectrum
45 antiviral effectors in two mammals – pigs and bats – identified as major reservoirs for
46 emerging viruses.

47

48

49 Introduction

50

51 Restriction factors are germline-encoded proteins that function in a cell-autonomous manner
52 to suppress virus replication. The interferon-induced transmembrane (IFITM) proteins are a
53 family of small interferon (IFN)-stimulated proteins, which affect diverse cellular processes
54 (reviewed in (Siegrist *et al.*, 2011)) and were recently identified as antiviral restriction factors
55 which inhibit cell entry of multiple pathogenic viruses (Brass *et al.*, 2009).

56

57 To date, IFITMs have been reported to restrict the enveloped viruses influenza A, West Nile
58 Virus and Dengue Virus (*Flaviviridae*), SARS-coronavirus, Ebola and Marburg viruses
59 (*Filoviridae*), Vesicular Stomatitis Virus (VSV) and lyssaviruses (*Rhabdoviridae*), HIV-1 and
60 several species of *Bunyaviridae*, as well as a non-enveloped orthoreovirus (*Reoviridae*)
61 (Anafu *et al.*, 2013; Brass *et al.*, 2009; Huang *et al.*, 2011; Jia *et al.*, 2012; Lu *et al.*, 2011;
62 Mudhasani *et al.*, 2013; Smith *et al.*, 2013; Weidner *et al.*, 2010). The common feature of
63 IFITM-sensitive viruses appears to be their dependence on acidic endosomal entry
64 pathways, either for proteolytic cleavage, or pH- or protease-dependent activation of viral
65 entry proteins into their fusogenic form. Accordingly, pseudotyped retroviruses expressing
66 heterologous surface envelope proteins recapitulate the IFITM sensitivity of the authentic
67 virus from which the envelope protein derives, and have been widely used to study IFITM
68 biology (Brass *et al.*, 2009; Feeley *et al.*, 2011; Huang *et al.*, 2011). The IFITMs localise to
69 membranes of late endosomes and lysosomes and prevent the release of viral particles from
70 these compartments into the cytosol (Feeley *et al.*, 2011).

71

72 The human *IFITM* gene family comprises *IFITM1*, *-2*, *-3*, *-5*, all of which possess antiviral
73 activity and cluster together on chromosome 11, as well as *IFITM10* whose function remains
74 unknown. Mice possess orthologues of all the human *IFITM* genes and two additional
75 genes, *Ifitm6* and *Ifitm7*. *IFITM1-3* are expressed in a wide range of tissues (Bailey *et al.*,

76 2012; Everitt *et al.*, 2013; Siegrist *et al.*, 2011) whereas IFITM5 expression is limited to
77 osteoblasts (Moffatt *et al.*, 2008). Of all the IFITMs, IFITM3 is the most potent anti-influenza
78 effector *in vitro* (Huang *et al.*, 2011). *Ifitm3* has a critical role in limiting influenza-induced
79 morbidity and mortality in mice (Everitt *et al.*, 2012). Since the phenotype of influenza-
80 infected *Ifitm3*^{-/-} mice was indistinguishable from that of mice deleted for the entire locus
81 (comprising *Ifitm1*, -2, -3, -5 and -6), *Ifitm3* apparently dominates influenza resistance *in vivo*
82 (Bailey *et al.*, 2012). Moreover, the importance of IFITM3 was highlighted by reports showing
83 that an *IFITM3* allele (rs12252-C) is associated with enhanced disease severity caused by
84 pandemic influenza H1N1/09 (Everitt *et al.*, 2012; Zhang *et al.*, 2013b) and highly
85 pathogenic influenza H7N9 (Wang *et al.*, 2014) and is more frequent in Chinese than
86 Caucasian populations.

87

88 IFITM proteins comprise a relatively long hydrophilic N-terminal region, two hydrophobic
89 intramembrane domains (IM1 and IM2), separated by a conserved intracellular loop (CIL),
90 and a comparatively short hydrophilic C-terminal region. The IM1 and CIL together constitute
91 the CD225 domain, a functionally poorly-defined domain shared by >300 members of the
92 CD225/pfam04505 protein superfamily. Several alternative topologies have been proposed
93 for the IFITMs (Chen *et al.*, 1984; Li *et al.*, 2013; Takahashi *et al.*, 1990; Yount *et al.*, 2012),
94 but the most recent study suggests that murine *Ifitm3* is a type II transmembrane protein,
95 comprising an intracellular N-terminus, an extracellular C-terminus and a membrane-
96 spanning 'IM2' domain (Bailey *et al.*, 2013). IFITM function is regulated by several post-
97 translational modifications. S-palmitoylation of IFITM3 on three membrane proximal cysteine
98 residues enhances membrane affinity and antiviral activity against influenza (Yount *et al.*,
99 2012; Yount *et al.*, 2010). Conversely, lysine-linked ubiquitination decreases IFITM3's co-
100 localisation with endolysosomes and its antiviral potency (Yount *et al.*, 2012). The Y20
101 residue, which can be phosphorylated by the tyrosine kinase Fyn, is critical for targeting

102 IFITM3 to endolysosomes and restriction of endosome-dependent viruses (Jia *et al.*, 2012;
103 John *et al.*, 2013).

104

105 Current evidence indicates that IFITMs block viral entry to the cytosol by preventing fusion
106 between viral and host cell membranes. IFITMs multimerise via their IM1 regions (John *et*
107 *al.*, 2013) and increase membrane rigidity (Li *et al.*, 2013). This suggests a model in which
108 IFITMs either physically resist the deformation of the membrane by the viral fusion
109 machinery or hinder the lateral mobility of viral or cellular proteins within the membrane and
110 thereby block successful pore formation (John *et al.*, 2013; Li *et al.*, 2013; Perreira *et al.*,
111 2013). Amini-Bavil-Olyaei *et al.* recently reported that IFITM3 interacts with a protein
112 involved with cholesterol homeostasis, vesicle-membrane-protein-associated protein A
113 (VAPA), and thereby causes cholesterol accumulation in multivesicular bodies and late
114 endosomes which inhibits the fusion between virion and endosomal membranes (Amini-
115 Bavil-Olyaei *et al.*, 2013). However, a unifying mechanism to explain antiviral restriction by
116 IFITM proteins remains elusive (Perreira *et al.*, 2013; Smith *et al.*, 2014). Indeed recent
117 reports showing that IFITM3 can be co-opted to promote cell entry of human coronavirus
118 OC43 (Zhao *et al.*, 2014) and human papillomavirus (Warren *et al.*, 2014) suggest virus-
119 specific IFITM interactions.

120

121 Although the *IFITM* gene family is evolutionary conserved in vertebrates (Hickford *et al.*,
122 2012; Zhang *et al.*, 2012), it is unclear whether antiviral activity is also conserved among
123 vertebrate IFITMs. Here, we focused on the bat and pig since these hosts are particularly
124 relevant to the ecology of several IFITM-sensitive zoonotic viruses.

125

126

127

128 **Results**

129

130 **Sequence analysis of IFITM3 orthologues cloned from microbat and pig cells**

131

132 In vertebrates, the *IFITM-1*, *-2*, *-3* and *-5* genes cluster together in an *IFITM* locus flanked by
133 the *B4GALNT4* and *ATHL1* genes. It was not possible to assign pig and bat IFITM3
134 orthologues based on conserved synteny due the lack of a *B4GALNT4* orthologue in pigs,
135 gaps in the genome assemblies, and the low sequencing coverage of the bat genomes (2.6-
136 X for *Pteropus vampyrus* and 1.7-X for *Myotis lucifugus* at the time of analysis). Therefore,
137 to identify *IFITM* genes, rapid amplification of cDNA ends (RACE) was performed on a
138 newborn pig trachea cell line (NPTr) and primary lung fibroblasts from the greater mouse-
139 eared bat, *Myotis myotis*, a European species of microbat (*Vespertilionidae*). *M. myotis* was
140 selected since it is a known reservoir host for several highly pathogenic viruses (Amengual
141 *et al.*, 2007; Drexler *et al.*, 2011; Drexler *et al.*, 2012) and genomes are available for other
142 species from the same genus (Seim *et al.*, 2013; Zhang *et al.*, 2013a).

143

144 RACE using primers designed to the conserved central regions of compiled *IFITM*-like
145 sequences yielded several *IFITM* gene variants, of which the designated IFITM3-like
146 sequences were the most abundant. For the pig, the IFITM3-like sequence was the only
147 IFITM variant identified which had an N-terminal extension typical of IFITM2/3 proteins
148 (compare human IFITM1-3 in Fig. 1b). For the microbat, the sequence we assigned as
149 IFITM3 was the most frequent of several long IFITM variants (68% of sequenced clones)
150 and the only one encoding a double phenylalanine motif (F8/F9) conserved in the human
151 and pig IFITM3 orthologues but absent from human IFITM2 (Fig. 1b).

152

153 Full-length *IFITM3* cDNA sequences were obtained by RT-PCR, and introns were identified
154 by PCR using genomic DNA, thereby confirming that these are not intron-less expressed

155 pseudogenes. The transcript structure for pig and microbat IFITM3 was the same as for
156 other experimentally verified IFITM3 orthologues, comprising two exons, a single intron of
157 similar size to other *IFITM3* genes and a conserved exon-exon junction site (Fig. 1a). BLAST
158 searches revealed that the *IFITM3* sequence from NPTr cells is identical to the *Sus scrofa*
159 *IFITM3* reference sequence (NM_001201382.1), and the closest match for the cloned
160 microbat IFITM3 was a 'predicted *IFITM3*-like' gene from *M. lucifugus* (XP_006108229.1,
161 95% amino acid identity).

162

163 Multiple sequence alignments showed that amino acid residues which are functionally
164 important in murine and human IFITM3 are conserved in the cloned pig and microbat
165 orthologues (Fig. 1b). These include (i) three cysteine residues which are S-palmitoylated
166 (Yount *et al.*, 2010), (ii) several lysine residues modified by ubiquitination (Yount *et al.*, 2012)
167 (including K88 which can be monomethylated (Shan *et al.*, 2013)), (iii) the Y20 residue
168 critical for endosomal targeting (Jia *et al.*, 2012; John *et al.*, 2013), (iv) two phenylalanine
169 residues (F75 and F78) which mediate oligomerisation (John *et al.*, 2013) and (v) R85, R87
170 and Y99 shown to influence antiviral restriction (John *et al.*, 2013). The microbat and pig
171 IFITM3 proteins are most divergent from human IFITM3 at their N and C termini, and most
172 conserved in the central CD225 domain, a pattern shared with other orthologues (chicken
173 and mouse Ifitm3) and paralogues (human IFITM2 and IFITM1) (Fig. 1b).

174

175 **Microbat and pig IFITM3 localize to transferrin and CD63 positive endosomes**

176

177 To analyse the IFITM3 proteins, A549 cells (which express low levels of endogenous IFITM3
178 (Brass *et al.*, 2009)) were stably transduced to express C-terminally HA-tagged IFITM3 from
179 pig, microbat or human. Prior work has shown that C-terminal epitope tags do not affect
180 function or expression levels of IFITM3, and indicate that tagged constructs adopt the same
181 topology as the wild type protein (Bailey *et al.*, 2013).

182

183 Similar to human IFITM3, both pig and microbat IFITM3 had a punctate intracellular
184 distribution following cell fixation and permeabilisation (Fig. 2a-c) and co-localised with
185 endocytosed transferrin (early endosomes) and with CD63, a marker for late endosomes/
186 multivesicular bodies (MVBs), but not with the lysosomal marker LAMP1 (Fig 2a-c). There
187 was an enlargement of CD63 positive structures in cells expressing microbat or human
188 IFITM3 in comparison to the smaller CD63 positive vesicles seen in pig IFITM3-expressing
189 or untransduced A549 cells (Fig. 2b). Enlargement of CD63-containing compartments was
190 most marked in cells containing larger foci of IFITM3-HA staining. Microbat IFITM3-HA
191 sometimes co-localised with CD63 in 'hollow' ring-like structures (arrows in Fig. 2b).

192

193 **Endocytic uptake of microbat and pig IFITM3 from the plasma membrane**

194

195 To investigate the trafficking of pig and microbat IFITM3s, live cells were incubated with
196 FITC-conjugated anti-HA antibody and Alexa 546-conjugated transferrin prior to fixation.
197 When labeling was performed on ice, endocytosis was prevented as indicated by the weak
198 stippled transferrin signal, likely corresponding to clathrin-coated pits pre-internalisation (Fig.
199 3a). Under these conditions, IFITM3 from the three species was detected on the plasma
200 membrane, clearly highlighting filopodia and membrane ruffles, while no vesicular staining
201 was observed. In contrast, when labeling was performed at 37°C to allow endocytosis, anti-
202 HA staining showed that pig, microbat and human IFITM3 formed discrete puncta, which, as
203 previously observed, overlapped or were closely associated with transferrin-positive
204 endosomes (Fig. 3b). For all IFITM3s, internalization of the anti-HA antibody by live cells
205 identified larger, brighter puncta that were more widely distributed within the cytosol
206 compared to the HA staining seen previously following fixation and permeabilisation
207 (indicating that permeabilisation may cause some extraction of the membrane associated
208 IFITM3). In conclusion, pig and microbat IFITM3 share the following with their human
209 counterpart: (i) plasma membrane trafficking (ii) extracellular exposure of their C-termini

210 (allowing detection of the C-terminal HA tag in intact cells) and (iii) endocytic uptake from the
211 plasma membrane into the endosomal pathway.

212

213 **Microbat and pig IFITM3 restrict cell entry mediated by influenza HA**

214

215 To determine whether pig and microbat IFITM3 restrict influenza A virus entry, lentiviruses
216 expressing the HA proteins from diverse influenza subtypes were used to infect A549 cells
217 that were untransduced or had been transduced to express either human IFITM3, pig
218 IFITM3 (Fig. 4a) or microbat IFITM3 (Fig. 4b). Three independently cloned cell lines of the
219 pig and microbat IFITM3s markedly inhibited the infectivity of all influenza HA subtypes
220 tested, including both Group 1 and Group 2 HAs and highly pathogenic avian H5 and H7
221 (Fig. 4). Pig or microbat IFITM3 did not restrict viruses pseudotyped with the entry proteins
222 of the gammaretroviruses amphotropic murine leukemia virus or Gibbon ape leukemia virus
223 (Fig. S1), consistent with previous studies on human IFITM3 (Brass *et al.*, 2009; Huang *et*
224 *al.*, 2011).

225

226

227 **Microbat and pig IFITM3 inhibit replication-competent influenza virus**

228

229 To assess the effect of the IFITM3 orthologues on replication-competent influenza virus,
230 untransduced A549 cells or cells expressing either human, pig or microbat IFITM3 were
231 infected with influenza A/WSN/33 (H1N1) and nucleoprotein (NP) expression was
232 quantitated using flow cytometry. Expression of either pig or microbat IFITM3 led to a
233 marked reduction in the proportion of NP positive cells for all cell clones (Fig. 5a). There was
234 slight variation in the degree of restriction between the three cell lines expressing pig IFITM3
235 (Fig. 5a and Fig. S2) despite comparable expression of IFITM3-HA seen by Western blot
236 (Fig. S2).

237

238 Stable expression of either pig, microbat or human IFITM3 in A549 cells significantly
239 reduced single cycle growth of influenza A/WSN/33 (Fig. 5c), consistent with reduced NP
240 expression measured in parallel (Fig 5b). Inhibition of virus yields was more profound
241 following low m.o.i. infection ($>1 \log_{10}$ for pig IFITM3 and $>2 \log_{10}$ for both microbat and
242 human IFITM3) relative to control GFP-expressing cells (Fig. 5d). A similar pattern of
243 restriction was also observed when NP expression was analysed after infections with an
244 avian-like swine influenza strain, A/swine/453/06 (H1N1) (Fig. 5b). Levels of the stably
245 expressed proteins were examined by Western blotting against the C-terminal HA epitope
246 tag, and showed that pig IFITM3, human IFITM3 and GFP-HA expression were comparable
247 while microbat IFITM3 was more highly expressed (Fig. 5c and Fig S3).

248

249 **Microbat and pig IFITM3 block cell entry mediated by lyssavirus entry proteins**

250

251 In light of data which suggest there may be virus-specific antiviral determinants of IFITM
252 (John *et al.*, 2013; Zhao *et al.*, 2014), it was of interest to explore the antiviral spectrum of
253 pig and microbat IFITM3, especially for viruses that naturally infect these species.

254

255 A549 cells stably expressing either pig, microbat or human IFITM3 were infected with
256 pseudotyped lentiviruses that expressed the envelope glycoproteins from isolates
257 representing different lyssavirus phylogroups, namely the rabies virus strain Evelyn Rokitniki
258 Abelseth (phylogroup 1), Mokola virus (phylogroup 2), Lagos bat virus (phylogroup 2) and
259 West Caucasian bat virus (phylogroup 3). Expression of IFITM3 from either microbat, pig or
260 human reduced infectivity mediated by all four lyssavirus entry proteins, in all cases by
261 approximately $2 \log_{10}$ relative to control cells (Fig. 6). Thus, the pig and microbat IFITM3
262 orthologues inhibit cell entry mediated by multiple lyssavirus G proteins.

263

264 **IFITM3 activity in pig and microbat cells**

265

266 Finally, we addressed the contribution of IFITM3 to antiviral responses in pig and microbat
267 cells. Endogenous IFITM3 expression was measured using Taqman qRT-PCR designed to
268 specifically detect IFITM3 mRNA and not other IFITM paralogues identified in these cells by
269 RACE. Baseline levels of IFITM3 mRNA were readily detected in both the porcine NPTr cells
270 (Ct value IFITM3: 22.7; Ct value GAPDH 21.33) and in microbat lung fibroblasts (Ct value
271 IFITM3: 25.8; Ct value GAPDH 22.8). IFITM3 induction was assessed in response to the
272 dsRNA analogue polyI:C, a molecular pattern associated with viral infection which is
273 recognised by toll-like receptor 3 and induces Type I IFN in porcine (Provost *et al.*, 2012)
274 and bat cells (Biesold *et al.*, 2011; Omatsu *et al.*, 2008; Zhou *et al.*, 2011). PolyI:C addition
275 led to a 3.5-fold increase in pig IFITM3 and a 2-fold increase in microbat IFITM3 mRNA
276 levels (Fig. 7). The microbat cells were also stimulated via polyI:C transfection since in
277 pteropid bat lung cells (but not primary cells from other tissues) this enhanced IFN β
278 induction relative to extracellular delivery of polyI:C (Zhou *et al.*, 2011). However,
279 transfection of polyI:C into microbat cells resulted in a similar degree of IFITM3 induction
280 (2.3-fold) (Fig. 7).

281

282 Next, the function of endogenous IFITM3 was assessed using siRNA designed using the
283 RACE sequence data to target IFITM3 and not other putative IFITM paralogues. siRNA
284 targeting IFITM3 or control non-targeting siRNAs were transfected into cells with polyI:C
285 induction of IFITM3. IFITM3 mRNA was quantified by qRT-PCR and the biological effect of
286 the knockdown assessed by infection with influenza A/WSN/33 (Fig. 8). Transfection of
287 siRNA against pig IFITM3 led to a 63% knockdown in IFITM3 mRNA (1.4 log₂ fold change)
288 (Fig. 8a), a 3.4-fold increase in virus yields (Fig. 8b) and a 2-fold increase in the proportion
289 of influenza NP positive cells (Fig. 8c) relative to control siRNA transfected cells. In the
290 absence of polyI:C stimulation, IFITM3 knockdown in NPTr cells increased influenza NP
291 positive cells more (3.3-fold) (Fig. 8d) suggesting additional polyI:C induced genes
292 complement IFITM3 mediated influenza virus restriction. Microbat IFITM3 knockdown in the
293 absence of polyI:C stimulation (Fig. 8e-g) reduced IFITM3 mRNA levels by 60% (1.3 log₂ fold

294 change) (Fig. 8e) and led to a 2-fold increase in infectious yields (Fig. 8f) and a 3-fold
295 increase in NP expression (Fig. 8g), relative to control siRNA transfection. Thus,
296 endogenous IFITM3 in pig tracheal NPT_r cells and microbat lung cells restricts influenza
297 virus. Lastly, following siRNA knockdown of baseline IFITM3 in a microbat cell line,
298 overexpression of microbat IFITM3 significantly inhibited influenza NP expression (Fig. S4).

299

300 **Discussion**

301 Species differences in restriction factors can determine differential viral susceptibility
302 (Duggal & Emerman, 2012; Fadel & Poeschla, 2011; Kirmaier *et al.*, 2010; McNatt *et al.*,
303 2009). However, antiviral immunity in reservoir and spill-over hosts remains poorly
304 understood, although important for understanding viral emergence (Bean *et al.*, 2013). Here
305 we show that IFITM3 proteins with broad-spectrum antiviral function are conserved in swine
306 and Chiroptera, hosts of numerous zoonotic viruses.

307

308 The RACE reactions used here capture multiple possible expressed IFITM paralogues by
309 using primers against the conserved CD225 domain. We assigned microbat IFITM3 using
310 several criteria. First, it encodes a double phenylalanine motif (F8/F9) found only in other
311 IFITM3 orthologues (whereas the other microbat IFITM variants resembled human IFITM2 in
312 having a single phenylalanine at this position). Secondly, microbat IFITM3 had an
313 intracellular location and co-localised with endosomal markers. Conserved genome synteny
314 was previously used to help assign IFITM genes (Smith *et al.*, 2013; Zhang *et al.*, 2012), but
315 was of limited use in the case of the poorly assembled IFITM loci in the pig and microbat
316 genomes. Moreover, the IFITM gene family is associated with numerous processed
317 pseudogenes, gene duplications and copy number variation (Siegrist *et al.*, 2011; Zhang *et al.*,
318 2012), which significantly complicates the assignment of gene orthology. Although, a
319 recent computational study identified 8 pig IFITM family members with expressed sequence
320 tag (EST) evidence (Miller *et al.*, 2014), it lacked the functional validation presented here.

321

322 Functionally important amino acid residues for human or mouse IFITM3 were conserved in
323 pig and microbat IFITM3, indicating that these may be functionally important sites across the
324 orthologues. Amino acid residues are less conserved within IM2 compared to IM1, although
325 IM2 can function as a signal anchor for membrane localisation (Bailey *et al.*, 2013) and is
326 also sufficient to mediate the IFITM3-VAPA interaction (Amini-Bavil-Olyaei *et al.*, 2013).

327

328 We show here that C-terminally HA-tagged IFITM3 (of human, pig and microbat) was clearly
329 detectable at the plasma membrane after live cell staining. These data support recent
330 evidence for a luminal (i.e. extracellular) exposure of the C-terminus (Bailey *et al.*, 2013),
331 and indicate that pig and microbat IFITM3 adopt a similar topology. Other studies have also
332 reported that a proportion of human IFITM3 localises to the plasma membrane (Amini-Bavil-
333 Olyaei *et al.*, 2013; Bailey *et al.*, 2013; Brass *et al.*, 2009), and it is thought that the 20-
334 YEML-23 motif acts as a lysosomal sorting signal for the internalisation of IFITM3 into the
335 endosomal pathway (Jia *et al.*, 2012; John *et al.*, 2013). Pig and microbat IFITM3 contain
336 20-YEML-23 and 20-YEVL-23 respectively (which conform to the consensus sequence for a
337 tyrosine-based sorting signal Yxx Φ , where Φ is a residue with a bulky hydrophobic side
338 chain (Bonifacino & Traub, 2003)), and likewise were observed to traffic into endosomes
339 following their cell surface staining. Pig and microbat IFITM3 co-localised with endocytosed
340 transferrin (early endosomes) and CD63 (late endosomes/ MVBs) as seen for human
341 IFITM3 (Figs. 2 and 3 and (Amini-Bavil-Olyaei *et al.*, 2013; Feeley *et al.*, 2011; Huang *et al.*,
342 2011; Jia *et al.*, 2012; Lu *et al.*, 2011). Expression of both microbat and human IFITM3
343 caused expansion of CD63 positive endosomal compartments, consistent with the
344 documented ability of IFITM3 to induce MVB formation (Amini-Bavil-Olyaei *et al.*, 2013).
345 Furthermore, in some cells microbat IFITM3 co-stained with CD63 in ring-like structures, a
346 phenomenon reported for human IFITM3 and enhanced by overexpression of its interaction
347 partner VAPA (Amini-Bavil-Olyaei *et al.*, 2013). In our hands neither human IFITM3 nor its
348 pig and microbat orthologues co-localised with the lysosomal marker LAMP1, which is
349 consistent with some (Yount *et al.*, 2010) but not other (Feeley *et al.*, 2011; Huang *et al.*,

2011) reports for IFITM3 localisation. These discrepancies regarding localisation may be due to IFITM3's multiple post-translational modifications (Yount *et al.*, 2012) and/or cell type-dependent differences in its topology (Bailey *et al.*, 2013).

We show that both pig and microbat IFITM3 restrict cell entry mediated by multiple influenza A virus HA (a class I fusion protein) and lyssavirus G proteins (a class III fusion protein). Restriction at the level of cell entry correlated with significant inhibition of influenza virus yields and NP expression. The microbat, pig and human IFITM3-expressing A549 cells varied in their IFITM3 expression levels, which may underlie variation seen in the degree of restriction. However, anti-influenza restriction by pig IFITM3 was in general lower than that seen for human IFITM3, despite comparable expression levels. We found that pig and human IFITM3 can restrict avian, swine and human influenza A subtypes. Similarly, chicken IFITM3 inhibited viral pseudotypes bearing HAs from both avian and human strains (Smith *et al.*, 2013). siRNA knockdown of endogenous pig and microbat IFITM3 enhanced influenza replication by a similar degree to that seen following knockdown of human IFITM3 (Huang *et al.*, 2011) or chicken IFITM3 (Smith *et al.*, 2013). IFITM3 was constitutively expressed in pig and bat cells (as reported for other IFITM3 orthologues (Bailey *et al.*, 2012; Everitt *et al.*, 2013; Everitt *et al.*, 2012; Friedman *et al.*, 1984; Smith *et al.*, 2013)). Baseline levels of IFITM3 in the pig and bat cells were sufficient to limit viral replication and, following siRNA targeting of baseline IFITM3, microbat IFITM3 was also capable of restricting influenza virus when overexpressed in microbat cells. Since pig IFITM3 was moderately induced by polyI:C and up-regulated upon viral challenge *in vivo* (Andersson *et al.*, 2011; Miller *et al.*, 2014), pig IFITM3 is likely to be relevant to host antiviral responses.

Here, we show that influenza A viruses and lyssaviruses, virus families which share an ancient co-evolutionary history with bats (Badrane & Tordo, 2001; Tong *et al.*, 2013) are restricted by microbat IFITM3. Bats harbour many diverse virus types and are important reservoirs of zoonotic infections (Drexler *et al.*, 2014; Quan *et al.*, 2013; Smith & Wang,

2013; Tong *et al.*, 2013). However, the basis for the intimate association between bats and viruses remains enigmatic, particularly the relative importance of immunological compared to ecological or life history factors (Kupferschmidt, 2013). Although transcriptional induction of chiropteran ISG orthologues is reported (Papenfuss *et al.*, 2012; Zhou *et al.*, 2013), there is a striking lack of functional data for any of these genes. We demonstrate that bats do encode functional IFITM3 and therefore are likely to be competent in this aspect of intrinsic antiviral restriction.

385

386 **Methods**

387

388 **Cells**

389 A549 cells were maintained in F12 medium, and 293T, NPTr cells (Ferrari *et al.*, 2003) and FLN-R cells (Cat No. CCLV-RIE 1091 (Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany) were grown in DMEM with 10% FCS. Primary lung cells from the microbat *Myotis myotis* were grown in DMEM containing 10% FCS, penicillin and streptomycin and 20% amnioMAX (Gibco).

394

395 **RACE & IFITM3 cloning**

396

397 NPTr and microbat cells were transfected with polyI:C (Invivogen, tlrI-pic) at 33ug/ml using Lipofectamine 2000 and 4h later total RNA and genomic DNA were isolated (Qiagen AllPrep Kit). 5' and 3' IFITM cDNA fragments were generated using the SMARTer RACE cDNA amplification kit (Clontech) and the following primers (designated by name): '5Bat': gccagagctatgctccaccgccaagtcc; '3Bat': cgtctggtccctgttcaacaccctcttc; '5Pig': gatgttcaggcacttggcggaggcatagctc; '3Pig': tgaactggtgctgcctgggcttcgtgg. PCR products were TA cloned and multiple clones sequenced using Sanger sequencing. Non-coding sequences identified by RACE were used to design primers for PCR amplification of full length IFITM3 ('BatIFITM3ncrF': gcatccacagccatctgctc; 'BatIFITM3ncrR':

406 gaacgccattgtgcacatgtgc; 'PigIFITM3ncrF': acagcttctctctgggcaccatg; 'PigIFITM3ncrR':
407 gtatgtgctgctgtgaaaggag). Pig IFITM3 and microbat IFITM3 were synthesized as codon-
408 optimised genes for expression in human cells (GeneArt) and cloned into the BamHI and
409 NotI sites of the lentivirus vector pSIN-BNHA (derived from pHRSIN-CSGW (Demaison *et*
410 *al.*, 2002)).

411

412 **Creation of IFITM3-expressing cell lines**

413 Lentiviruses expressing IFITM3 (or GFP as a control) were produced by co-transfecting
414 293T cells using Fugene HD with the packaging plasmid p8.91 (Zufferey *et al.*, 1997) (1ug),
415 the VSV-G expressing plasmid pMDG (1ug) and the lentivirus vector pSIN-BNHA (1.5ug)
416 containing either pig IFITM3, microbat IFITM3 or GFP. Supernatants were harvested at 48h
417 and 72h, filtered (0.45um) and used to transduce A549 cells. Transduction efficiency was
418 checked after 48h via flow cytometric detection of HA. Single cell clones were generated
419 using limiting dilution and analysed for HA expression. Those with the most similar
420 expression levels were selected for experiments. Human IFITM3-expressing A549 cells
421 were generated using the same method (Smith *et al.*, 2013).

422

423 **Pseudotyped lentivirus cell entry assay**

424 Lentiviral pseudotypes were produced as previously (Ferrara *et al.*, 2012; Wright *et al.*,
425 2008). For the entry assay, A549 cells were seeded in white 96 well plates (1e4 cells/ well)
426 one day prior to infection with luciferase-expressing pseudotypes expressing influenza
427 hemagglutinin (HA) (H1: GenBank accession AAD17229.1; H5: ABP51969.1; H10:
428 ABI84534.1; H14: BAF43460.1; H7: CAD37074.1; H3: AAA43099.1; H15: AAA96134.1), the
429 G proteins from Mokola virus (MOKV.98/071 RA361: GQ500108), Lagos Bat Virus
430 (LBV.NIG56-RV1: HM623779), West Caucasian Bat Virus (WCBV: AAR03484) or Evelyn
431 Rokitniki Abelseth rabies strain (ERA: ABN11294) or MLV-A or GALV envelope proteins.
432 The H1 and H3 HAs were human in origin, and the other HA subtypes were avian in origin.

433 Cells were infected in triplicate and 48h later luciferase activity was measured using the
434 Bright Glo luciferase assay system (Promega).

435

436 **siRNA transfection and Real-Time PCR**

437 siRNAs against pig IFITM3 (GCTCATAAAGGATTACAGA) or microbat IFITM3
438 (CGAGGACGACGGTGGTCAA) (Dharmacon, ON-TARGETplus) were designed using
439 knowledge of other IFITM paralogues and the Dharmacon siDesign Centre. The ON-
440 TARGETplus non-targeting siRNA pool and an siRNA targeting GFP (P-002048-01-20) were
441 used as controls. siRNA was transfected into cells (20pmol per well of a 12 well plate) using
442 Lipofectamine RNAiMAX. 48h later, RNA was extracted (RNeasy kit, Qiagen) and the
443 Quantitect multiplex RT-PCR kit (Qiagen) was used to measure IFITM3 and GAPDH
444 simultaneously using TaqMan gene expression assays (Applied biosystems, primer
445 sequences available on request). MxPro software was used for comparative quantitation of
446 IFITM3 relative to the GAPDH reference gene.

447

448 **Flow cytometry**

449 Cells were infected in triplicate with influenza A/WSN/33 in media containing 2% FCS. Cells
450 were trypsinised, fixed using BD Fixation/Permeabilisation solution for 20 min and washed
451 twice in BD Perm/Wash buffer before incubation with FITC-conjugated anti-influenza NP IgG
452 (Abcam ab20921) for 40 min at 4 °C. After staining, cells were washed, resuspended in PBS
453 and analysed using a Becton Dickinson FACSCalibur and Cell Quest Pro. For each sample,
454 10,000 cells (gated by forward and side scatter) were analysed for FITC fluorescence.

455

456 **Western blotting**

457 After cell lysis using RIPA buffer, proteins were separated by SDS-PAGE (4-12% TGX gel)
458 and transferred to nitrocellulose membrane. After blocking (5% Marvel, 0.1% Tween-20 in
459 PBS), membranes were incubated for 1h at room temperature with antibodies against
460 influenza NP (Abcam clone C43), beta-actin (Abcam ab8227) or the HA tag (Abcam clone

461 HA.C5). HRP-conjugated secondary antibodies were used followed by enhanced
462 chemiluminescent detection.

463

464 **Virus yield assay**

465 Cells were infected in triplicate with influenza A/WSN/33 in media containing 2% FCS. After
466 1h infection at 37°C, cells were washed thrice in PBS. At the indicated times post infection,
467 supernatants were harvested and the virus yields titered on MDCK cells by plaque assay
468 (Matrosovich *et al.*, 2006).

469

470 **Immunofluorescence**

471

472 Cells were fixed with 4% paraformaldehyde (20 min at room temperature). For transferrin co-
473 localisation, cells were pre-incubated with Alexa 546-conjugated transferrin (Molecular
474 Probes, 5ug/ml) for 10 min before fixation. Cells were permeabilised using 0.2% Triton X-
475 100, blocked using antibody buffer (0.1% Tween 20 and 10% goat serum in PBS) and
476 stained with FITC-conjugated anti-HA (Bethyl Laboratories A190-108F), anti-LAMP1 (Abcam
477 clone H4A3) or anti-CD63 (Santa Cruz MX-49.129.5) for 1 h at room temperature. Dylight
478 594-conjugated goat anti-mouse IgG was used to detect anti-CD63 and anti-LAMP1
479 antibodies. Live cell staining was performed either at 37°C or on ice, with solutions
480 equilibrated accordingly. Cells were washed twice in serum-free media before incubation for
481 30 min with FITC conjugated anti-HA and Alexa 546-conjugated transferrin (in serum free
482 media). Cells were then quickly washed in PBS and immediately fixed using 4%
483 paraformaldehyde (20 min). Coverslips were mounted using ProLong Gold reagent with
484 DAPI and examined with a Zeiss LSM 780 confocal microscope.

485

486 **Sequence analysis**

487 Multiple sequence alignments were performed using Clustal O (1.2.0) and Seaview (Gouy *et*
488 *al.*, 2010) was used for manual editing.

489

490 **Acknowledgements**

491

492 This work was supported by an award to C. Benfield from the Royal Veterinary College
493 Internal Grant Scheme (IGS 2930) and by the Wellcome Trust grant (098051) and the MRC
494 grant (G1000413).

495

496 We are grateful to Prof Malcolm Ferguson-Smith for supplying the primary bat cells, to Prof
497 Martin Beer (Friedrich-Loeffler-Institut) for providing FLN-R cells, to Prof Wendy Barclay for
498 supplying influenza virus, to Dr Fengtang Yang and Beiyuan Fu for their assistance with
499 primary cell culture, to Dr Mike Hollinshead for microscopy support, to Dr Matt Cotten and Dr
500 Simon Watson for bioinformatics assistance and to Dr Laurence Tiley, Dr Barbara Blacklaws
501 and Dr Dirk Werling for helpful discussions.

502

503

504

505 REFERENCES

- 506 **Amengual, B., Bourhy, H., Lopez-Roig, M. & Serra-Cobo, J. (2007).** Temporal
 507 dynamics of European bat Lyssavirus type 1 and survival of *Myotis myotis* bats
 508 in natural colonies. *PLoS One* **2**, e566.
- 509 **Amini-Bavil-Olyaei, S., Choi, Y. J., Lee, J. H., Shi, M., Huang, I. C., Farzan, M. & Jung, J.
 510 U. (2013).** The antiviral effector IFITM3 disrupts intracellular cholesterol
 511 homeostasis to block viral entry. *Cell host & microbe* **13**, 452-464.
- 512 **Anafu, A. A., Bowen, C. H., Chin, C. R., Brass, A. L. & Holm, G. H. (2013).** Interferon-
 513 inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. *The
 514 Journal of biological chemistry* **288**, 17261-17271.
- 515 **Andersson, M., Ahlberg, V., Jensen-Waern, M. & Fossum, C. (2011).** Intestinal gene
 516 expression in pigs experimentally co-infected with PCV2 and PPV. *Veterinary
 517 immunology and immunopathology* **142**, 72-80.
- 518 **Badrane, H. & Tordo, N. (2001).** Host switching in Lyssavirus history from the
 519 Chiroptera to the Carnivora orders. *J Virol* **75**, 8096-8104.
- 520 **Bailey, C. C., Huang, I. C., Kam, C. & Farzan, M. (2012).** Ifitm3 limits the severity of
 521 acute influenza in mice. *PLoS Pathog* **8**, e1002909.
- 522 **Bailey, C. C., Kondur, H. R., Huang, I. C. & Farzan, M. (2013).** Interferon-induced
 523 transmembrane protein 3 is a type II transmembrane protein. *The Journal of
 524 biological chemistry* **288**, 32184-32193.
- 525 **Bean, A. G., Baker, M. L., Stewart, C. R., Cowled, C., Deffrasnes, C., Wang, L. F. &
 526 Lowenthal, J. W. (2013).** Studying immunity to zoonotic diseases in the natural
 527 host - keeping it real. *Nature reviews Immunology* **13**, 851-861.
- 528 **Biesold, S. E., Ritz, D., Gloza-Rausch, F., Wollny, R., Drexler, J. F., Corman, V. M.,
 529 Kalko, E. K., Oppong, S., Drosten, C. & other authors (2011).** Type I interferon
 530 reaction to viral infection in interferon-competent, immortalized cell lines from
 531 the African fruit bat *Eidolon helvum*. *PLoS One* **6**, e28131.
- 532 **Bonifacino, J. S. & Traub, L. M. (2003).** Signals for sorting of transmembrane proteins
 533 to endosomes and lysosomes. *Annual review of biochemistry* **72**, 395-447.
- 534 **Brass, A. L., Huang, I. C., Benita, Y., John, S. P., Krishnan, M. N., Feeley, E. M., Ryan, B.
 535 J., Weyer, J. L., van der Weyden, L. & other authors (2009).** The IFITM
 536 proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus,
 537 and dengue virus. *Cell* **139**, 1243-1254.
- 538 **Chen, Y. X., Welte, K., Gebhard, D. H. & Evans, R. L. (1984).** Induction of T cell
 539 aggregation by antibody to a 16kd human leukocyte surface antigen. *J Immunol*
 540 **133**, 2496-2501.
- 541 **Demaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M. &
 542 Thrasher, A. J. (2002).** High-level transduction and gene expression in
 543 hematopoietic repopulating cells using a human immunodeficiency [correction
 544 of immunodeficiency] virus type 1-based lentiviral vector containing an internal
 545 spleen focus forming virus promoter. *Human gene therapy* **13**, 803-813.
- 546 **Drexler, J. F., Corman, V. M. & Drosten, C. (2014).** Ecology, evolution and
 547 classification of bat coronaviruses in the aftermath of SARS. *Antiviral research*
 548 **101**, 45-56.
- 549 **Drexler, J. F., Corman, V. M., Wegner, T., Tateno, A. F., Zerbinati, R. M., Gloza-
 550 Rausch, F., Seebens, A., Muller, M. A. & Drosten, C. (2011).** Amplification of
 551 emerging viruses in a bat colony. *Emerging infectious diseases* **17**, 449-456.

552 **Drexler, J. F., Corman, V. M., Muller, M. A., Maganga, G. D., Vallo, P., Binger, T.,**
553 **Gloza-Rausch, F., Rasche, A., Yordanov, S. & other authors (2012).** Bats host
554 major mammalian paramyxoviruses. *Nat Commun* **3**, 796.

555 **Duggal, N. K. & Emerman, M. (2012).** Evolutionary conflicts between viruses and
556 restriction factors shape immunity. *Nature reviews Immunology* **12**, 687-695.

557 **Everitt, A. R., Clare, S., McDonald, J. U., Kane, L., Harcourt, K., Ahras, M., Lall, A.,**
558 **Hale, C., Rodgers, A. & other authors (2013).** Defining the range of pathogens
559 susceptible to Ifitm3 restriction using a knockout mouse model. *PLoS One* **8**,
560 e80723.

561 **Everitt, A. R., Clare, S., Pertel, T., John, S. P., Wash, R. S., Smith, S. E., Chin, C. R.,**
562 **Feeley, E. M., Sims, J. S. & other authors (2012).** IFITM3 restricts the morbidity
563 and mortality associated with influenza. *Nature* **484**, 519-523.

564 **Fadel, H. J. & Poeschla, E. M. (2011).** Retroviral restriction and dependency factors in
565 primates and carnivores. *Veterinary immunology and immunopathology* **143**,
566 179-189.

567 **Feeley, E. M., Sims, J. S., John, S. P., Chin, C. R., Pertel, T., Chen, L. M., Gaiha, G. D.,**
568 **Ryan, B. J., Donis, R. O. & other authors (2011).** IFITM3 inhibits influenza A
569 virus infection by preventing cytosolic entry. *PLoS Pathog* **7**, e1002337.

570 **Ferrara, F., Molesti, E., Bottcher-Friebertshauer, E., Cattoli, G., Corti, D., Scott, S. D.**
571 **& Temperton, N. J. (2012).** The human Transmembrane Protease Serine 2 is
572 necessary for the production of Group 2 influenza A virus pseudotypes. *Journal of*
573 *molecular and genetic medicine : an international journal of biomedical research*
574 **7**, 309-314.

575 **Ferrari, M., Scalvini, A., Losio, M. N., Corradi, A., Soncini, M., Bignotti, E., Milanesi,**
576 **E., Ajmone-Marsan, P., Barlati, S. & other authors (2003).** Establishment and
577 characterization of two new pig cell lines for use in virological diagnostic
578 laboratories. *Journal of virological methods* **107**, 205-212.

579 **Friedman, R. L., Manly, S. P., McMahan, M., Kerr, I. M. & Stark, G. R. (1984).**
580 Transcriptional and posttranscriptional regulation of interferon-induced gene
581 expression in human cells. *Cell* **38**, 745-755.

582 **Gouy, M., Guindon, S. & Gascuel, O. (2010).** SeaView version 4: A multiplatform
583 graphical user interface for sequence alignment and phylogenetic tree building.
584 *Molecular biology and evolution* **27**, 221-224.

585 **Hickford, D., Frankenberg, S., Shaw, G. & Renfree, M. B. (2012).** Evolution of
586 vertebrate interferon inducible transmembrane proteins. *BMC Genomics* **13**, 155.

587 **Huang, I. C., Bailey, C. C., Weyer, J. L., Radoshitzky, S. R., Becker, M. M., Chiang, J. J.,**
588 **Brass, A. L., Ahmed, A. A., Chi, X. & other authors (2011).** Distinct patterns of
589 IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A
590 virus. *PLoS Pathog* **7**, e1001258.

591 **Jia, R., Pan, Q., Ding, S., Rong, L., Liu, S. L., Geng, Y., Qiao, W. & Liang, C. (2012).** The
592 N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3
593 cellular localization. *J Virol* **86**, 13697-13707.

594 **John, S. P., Chin, C. R., Perreira, J. M., Feeley, E. M., Aker, A. M., Savidis, G., Smith, S.**
595 **E., Elia, A. E., Everitt, A. R. & other authors (2013).** The CD225 domain of
596 IFITM3 is required for both IFITM protein association and inhibition of influenza
597 A virus and dengue virus replication. *J Virol* **87**, 7837-7852.

598 **Kirmaier, A., Wu, F., Newman, R. M., Hall, L. R., Morgan, J. S., O'Connor, S., Marx, P.**
599 **A., Meythaler, M., Goldstein, S. & other authors (2010).** TRIM5 suppresses

600 cross-species transmission of a primate immunodeficiency virus and selects for
601 emergence of resistant variants in the new species. *PLoS biology* **8**.

602 **Kupferschmidt, K. (2013)**. Emerging infectious diseases. Link to MERS virus
603 underscores bats' puzzling threat. *Science* **341**, 948-949.

604 **Li, K., Markosyan, R. M., Zheng, Y. M., Golfetto, O., Bungart, B., Li, M., Ding, S., He, Y.,**
605 **Liang, C. & other authors (2013)**. IFITM proteins restrict viral membrane
606 hemifusion. *PLoS Pathog* **9**, e1003124.

607 **Lu, J., Pan, Q., Rong, L., He, W., Liu, S. L. & Liang, C. (2011)**. The IFITM proteins inhibit
608 HIV-1 infection. *J Virol* **85**, 2126-2137.

609 **Matrosovich, M., Matrosovich, T., Garten, W. & Klenk, H. D. (2006)**. New low-
610 viscosity overlay medium for viral plaque assays. *Virology journal* **3**, 63.

611 **McNatt, M. W., Zang, T., Hatzioannou, T., Bartlett, M., Fofana, I. B., Johnson, W. E.,**
612 **Neil, S. J. & Bieniasz, P. D. (2009)**. Species-specific activity of HIV-1 Vpu and
613 positive selection of tetherin transmembrane domain variants. *PLoS Pathog* **5**,
614 e1000300.

615 **Miller, L. C., Jiang, Z., Sang, Y., Harhay, G. P. & Lager, K. M. (2014)**. Evolutionary
616 characterization of pig interferon-inducible transmembrane gene family and
617 member expression dynamics in tracheobronchial lymph nodes of pigs infected
618 with swine respiratory disease viruses. *Veterinary immunology and*
619 *immunopathology* **159**, 180-191.

620 **Moffatt, P., Gaumond, M. H., Salois, P., Sellin, K., Bessette, M. C., Godin, E., de**
621 **Oliveira, P. T., Atkins, G. J., Nanci, A. & other authors (2008)**. Bril: a novel
622 bone-specific modulator of mineralization. *Journal of bone and mineral research :*
623 *the official journal of the American Society for Bone and Mineral Research* **23**,
624 1497-1508.

625 **Mudhasani, R., Tran, J. P., Retterer, C., Radoshitzky, S. R., Kota, K. P., Altamura, L.**
626 **A., Smith, J. M., Packard, B. Z., Kuhn, J. H. & other authors (2013)**. IFITM-2
627 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. *J Virol* **87**, 8451-
628 8464.

629 **Omatsu, T., Bak, E. J., Ishii, Y., Kyuwa, S., Tohya, Y., Akashi, H. & Yoshikawa, Y.**
630 **(2008)**. Induction and sequencing of Rousette bat interferon alpha and beta
631 genes. *Veterinary immunology and immunopathology* **124**, 169-176.

632 **Papenfuss, A. T., Baker, M. L., Feng, Z. P., Tachedjian, M., Cramer, G., Cowled, C., Ng,**
633 **J., Janardhana, V., Field, H. E. & other authors (2012)**. The immune gene
634 repertoire of an important viral reservoir, the Australian black flying fox. *BMC*
635 *Genomics* **13**, 261.

636 **Perreira, J. M., Chin, C. R., Feeley, E. M. & Brass, A. L. (2013)**. IFITMs Restrict the
637 Replication of Multiple Pathogenic Viruses. *Journal of molecular biology* **425**,
638 4937-4955.

639 **Provost, C., Jia, J. J., Music, N., Levesque, C., Lebel, M. E., del Castillo, J. R., Jacques, M.**
640 **& Gagnon, C. A. (2012)**. Identification of a new cell line permissive to porcine
641 reproductive and respiratory syndrome virus infection and replication which is
642 phenotypically distinct from MARC-145 cell line. *Virology journal* **9**, 267.

643 **Quan, P. L., Firth, C., Conte, J. M., Williams, S. H., Zambrana-Torrel, C. M.,**
644 **Anthony, S. J., Ellison, J. A., Gilbert, A. T., Kuzmin, I. V. & other authors**
645 **(2013)**. Bats are a major natural reservoir for hepaciviruses and pegiviruses.
646 *Proceedings of the National Academy of Sciences of the United States of America*
647 **110**, 8194-8199.

648 **Seim, I., Fang, X., Xiong, Z., Lobanov, A. V., Huang, Z., Ma, S., Feng, Y., Turanov, A. A.,**
649 **Zhu, Y. & other authors (2013).** Genome analysis reveals insights into
650 physiology and longevity of the Brandt's bat *Myotis brandtii*. *Nat Commun* **4**,
651 2212.

652 **Shan, Z., Han, Q., Nie, J., Cao, X., Chen, Z., Yin, S., Gao, Y., Lin, F., Zhou, X. & other**
653 **authors (2013).** Negative Regulation of Interferon-induced Transmembrane
654 Protein 3 by SET7-mediated Lysine Monomethylation. *The Journal of biological*
655 *chemistry* **288**, 35093-35103.

656 **Siegrist, F., Ebeling, M. & Certa, U. (2011).** The small interferon-induced
657 transmembrane genes and proteins. *Journal of interferon & cytokine research :*
658 *the official journal of the International Society for Interferon and Cytokine*
659 *Research* **31**, 183-197.

660 **Smith, I. & Wang, L. F. (2013).** Bats and their virome: an important source of emerging
661 viruses capable of infecting humans. *Current opinion in virology* **3**, 84-91.

662 **Smith, S., Weston, S., Kellam, P. & Marsh, M. (2014).** IFITM proteins-cellular
663 inhibitors of viral entry. *Current opinion in virology* **4C**, 71-77.

664 **Smith, S. E., Gibson, M. S., Wash, R. S., Ferrara, F., Wright, E., Temperton, N., Kellam,**
665 **P. & Fife, M. (2013).** Chicken interferon-inducible transmembrane protein 3
666 restricts influenza viruses and lyssaviruses in vitro. *J Virol* **87**, 12957-12966.

667 **Takahashi, S., Doss, C., Levy, S. & Levy, R. (1990).** TAPA-1, the target of an
668 antiproliferative antibody, is associated on the cell surface with the Leu-13
669 antigen. *J Immunol* **145**, 2207-2213.

670 **Tong, S., Zhu, X., Li, Y., Shi, M., Zhang, J., Bourgeois, M., Yang, H., Chen, X., Recuenco,**
671 **S. & other authors (2013).** New world bats harbor diverse influenza A viruses.
672 *PLoS Pathog* **9**, e1003657.

673 **Wang, Z., Zhang, A., Wan, Y., Liu, X., Qiu, C., Xi, X., Ren, Y., Wang, J., Dong, Y. & other**
674 **authors (2014).** Early hypercytokinemia is associated with interferon-induced
675 transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection.
676 *Proceedings of the National Academy of Sciences of the United States of America*
677 **111**, 769-774.

678 **Warren, C. J., Griffin, L. M., Little, A. S., Huang, I. C., Farzan, M. & Pyeon, D. (2014).**
679 The Antiviral Restriction Factors IFITM1, 2 and 3 Do Not Inhibit Infection of
680 Human Papillomavirus, Cytomegalovirus and Adenovirus. *PLoS One* **9**, e96579.

681 **Weidner, J. M., Jiang, D., Pan, X. B., Chang, J., Block, T. M. & Guo, J. T. (2010).**
682 Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit
683 vesicular stomatitis virus infection via distinct mechanisms. *J Virol* **84**, 12646-
684 12657.

685 **Wright, E., Temperton, N. J., Marston, D. A., McElhinney, L. M., Fooks, A. R. & Weiss,**
686 **R. A. (2008).** Investigating antibody neutralization of lyssaviruses using
687 lentiviral pseudotypes: a cross-species comparison. *J Gen Virol* **89**, 2204-2213.

688 **Yount, J. S., Karssemeijer, R. A. & Hang, H. C. (2012).** S-palmitoylation and
689 ubiquitination differentially regulate interferon-induced transmembrane protein
690 3 (IFITM3)-mediated resistance to influenza virus. *The Journal of biological*
691 *chemistry* **287**, 19631-19641.

692 **Yount, J. S., Molledo, B., Yang, Y. Y., Charron, G., Moran, T. M., Lopez, C. B. & Hang, H.**
693 **C. (2010).** Palmitoylome profiling reveals S-palmitoylation-dependent antiviral
694 activity of IFITM3. *Nature chemical biology* **6**, 610-614.

695 **Zhang, G., Cowled, C., Shi, Z., Huang, Z., Bishop-Lilly, K. A., Fang, X., Wynne, J. W.,**
696 **Xiong, Z., Baker, M. L. & other authors (2013a).** Comparative analysis of bat

697 genomes provides insight into the evolution of flight and immunity. *Science* **339**,
698 456-460.

699 **Zhang, Y. H., Zhao, Y., Li, N., Peng, Y. C., Giannoulatou, E., Jin, R. H., Yan, H. P., Wu, H.,**
700 **Liu, J. H. & other authors (2013b).** Interferon-induced transmembrane
701 protein-3 genetic variant rs12252-C is associated with severe influenza in
702 Chinese individuals. *Nat Commun* **4**, 1418.

703 **Zhang, Z., Liu, J., Li, M., Yang, H. & Zhang, C. (2012).** Evolutionary dynamics of the
704 interferon-induced transmembrane gene family in vertebrates. *PLoS One* **7**,
705 e49265.

706 **Zhao, X., Guo, F., Liu, F., Cuconati, A., Chang, J., Block, T. M. & Guo, J. T. (2014).**
707 Interferon induction of IFITM proteins promotes infection by human coronavirus
708 OC43. *Proceedings of the National Academy of Sciences of the United States of*
709 *America* **111**, 6756-6761.

710 **Zhou, P., Cowled, C., Wang, L. F. & Baker, M. L. (2013).** Bat Mx1 and Oas1, but not Pkr
711 are highly induced by bat interferon and viral infection. *Developmental and*
712 *comparative immunology* **40**, 240-247.

713 **Zhou, P., Cowled, C., Todd, S., Cramer, G., Virtue, E. R., Marsh, G. A., Klein, R., Shi, Z.,**
714 **Wang, L. F. & other authors (2011).** Type III IFNs in pteropid bats: differential
715 expression patterns provide evidence for distinct roles in antiviral immunity. *J*
716 *Immunol* **186**, 3138-3147.

717 **Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. (1997).** Multiply
718 attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nature*
719 *biotechnology* **15**, 871-875.

720

721

722

723

724 **Figure Legends**

725

726 **Figure 1. Multiple sequence alignments with microbat and pig IFITM3.** (a) Pig and
727 microbat IFITM3 nucleotide sequences were aligned with experimentally verified IFITM3
728 orthologues. The intron-exon boundary is shown (exon1: black, exon 2: blue) and intronic
729 sequences flanking the splice sites are in red lower case. * denotes identical nucleotides. (b)
730 Pig and microbat IFITM3 amino acid sequences were aligned with other IFITM proteins. ‘*’
731 indicates identical amino acid residues, ‘:’ indicates residues with strongly similar properties,
732 ‘.’ indicates residues with weakly similar properties. The arrow indicates the exon-exon
733 boundary. Protein domains of human IFITM3 are shown (according to (John *et al.*, 2013))
734 (intramembrane domain 1 (IM1), conserved intracellular loop (CIL) and intramembrane
735 domain 2 (IM2)). Highlighted residues are discussed within the text.

736

737 **Figure 2. Subcellular localization of IFITM3 proteins.** A549 cells stably expressing HA-
738 tagged IFITM3 proteins from human, pig or microbat (or untransduced cells) were fixed,
739 permeabilised and stained for HA, CD63 (b) or LAMP1 (c). In (a) cells were incubated with
740 Alexa 546-conjugated transferrin before fixation and staining with FITC-conjugated anti-HA.
741 Nuclei were stained with DAPI and coverslips examined by confocal microscopy. Images
742 show representative staining patterns. Scale bar measures 10 um. Arrows in (b) identify
743 ‘ring-like’ staining of microbat IFITM3-HA and CD63.

744

745 **Figure 3. Endocytic uptake of IFITM3 proteins.** Live A549 cells expressing HA-tagged
746 IFITM3 from human, pig or microbat (or untransduced cells) were incubated either on ice (a)
747 or at 37°C (b) with FITC-conjugated anti-HA and Alexa 546-conjugated transferrin. After cell
748 fixation, nuclei were stained with DAPI, and coverslips examined by confocal microscopy.
749 Scale bar measures 10 um.

750

751 **Figure 4. Microbat and pig IFITM3 inhibit influenza HA-mediated cell**

752 **entry.** A549 cells stably expressing IFITM3 from human, pig (**a**) or microbat (**b**)
753 (or untransduced cells) were infected with pseudotyped viruses which express different
754 influenza HA glycoproteins. 48h post-infection, luciferase reporter activity was measured and
755 normalized to untransduced cells (relative infectivity of 1 corresponds to 3,000-5,000 relative
756 light units according to pseudotype used). Mean+ SD is shown (n=3) and data is
757 representative of 3 independent experiments.

758

759 **Figure 5. Microbat and pig IFITM3 inhibit influenza virus replication.** A549 cells stably
760 expressing human, pig or microbat IFITM3 were infected with influenza A virus. In (**b**)-(d) pig
761 IFITM3 clone 1 and microbat IFITM3 clone 2 were used. (**a**) 7h post-infection with influenza
762 A/WSN/33 NP expression was analysed by flow cytometry. (**b**) 16h after infection with
763 influenza A/WSN/33 or A/swine/453/06 or mock-infection (-V) cells were lysed and Western
764 blotting performed to detect influenza NP, actin and HA-tagged IFITM3 or GFP. Molecular
765 weight (MW) of protein size markers is indicated. Virus yields following infection with
766 influenza A/WSN/33 at m.o.i. 3 (**c**) or m.o.i. 0.01 (**d**) were measured using plaque assays.
767 Mean+ SD is shown (n=3). *: p<0.05, **: p<0.01 and ****:p<0.0001 relative to GFP-
768 expressing cells (Student's *t* test).

769

770 **Figure 6. Microbat and pig IFITM3 inhibit cell entry mediated by lyssavirus G proteins.**

771 A549 cells stably expressing either GFP, human IFITM3, pig IFITM3 (clone 1) or microbat
772 IFITM3 (clone 2) were infected with pseudotyped viruses which express the envelope
773 glycoprotein from MOKV (Mokola virus), WCBV (West Caucasian Bat Virus), LBV (Lagos
774 Bat Virus) or ERA (Evelyn Rokitniki Abelseth rabies strain). 48h post-infection, luciferase
775 reporter activity was measured and normalized to GFP-expressing cells (relative infectivity of
776 1 corresponds to 25,000-80,000 relative light units according to pseudotype used). Mean+
777 SD is shown (n=3) and data is representative of 3 independent experiments.

778

779 **Figure 7. Microbat and pig IFITM3 are polyI:C responsive.** Pig NPTr (a) and microbat (b)
780 cells were either mock-treated or stimulated by addition of polyI:C to cell media (50ug/ml) or
781 transfection of polyI:C (33ug/ml) using Lipofectamine 2000 (microbat cells only). 7h later
782 qRT-PCR was used to quantitate IFITM3 and the reference gene GAPDH. Fold change in
783 IFITM3 mRNA is expressed relative to mock-treated cells. Mean+ SD shown for biological
784 triplicates assayed in duplicate.

785

786 **Figure 8. siRNA knockdown of IFITM3 in pig and microbat cells enhances influenza**
787 **virus replication.** Pig NPTr or microbat cells were transfected with siRNA targeting IFITM3
788 or control siRNA prior to quantitation of IFITM3 by qRT-PCR (a & e) or infection with
789 influenza A/WSN/33. Virus yields were measured by plaque assay (b, f) or NP expression
790 was measured using flow cytometry (c, d, g). NPTr cells were either stimulated with polyI:C
791 for 2h before infection (m.o.i. 0.01) and analysed 36 h post-infection (b & c) or otherwise
792 cells were infected in the absence of polyI:C. Mean+ SD shown for biological triplicates
793 assayed in duplicate and data is representative of 2 independent experiments. *: p<0.05 and
794 **: p<0.01 (Student's *t* test).

795

796

797

798

Figure 1
[Click here to download Figure: Figure1.pdf](#)

(a)

Exon 1

```

CHICKEN_IFITM3 -----ATGGAGCGGTACGCGCTTCGGGTCGGGAGTCCACCG---TAT 42
MOUSE_IFITM3  ATGAACCACACTCTCAAGCCTTCATCCAGCTGCCAGTGGAGGACGCCCAACTAC 60
MICROBAT_IFITM3 ATGAACCCCACTCCAGCCCTCTCTCTGGCCGCCGCCGGAGTGTCCCATCTCTAT 60
PIG_IFITM3     ATGAAGTGGCTCCAGCCCTCTCTCACTGGTGCCTATGGAGGA---CCCCAATAT 57
HUMAN_IFITM3   ATGAATCACACTGTCAACACTCTCTCTCTCTCAACAGTGGCCAGCCGCCCAACTAT 60

```

GAACCCCTGATGGAGGGATGGAC-----ATGGAGGGGAG----- 78
 GAAGAATCAAGGAAGAAATAGAGTGGTGGATGGGGCACCACAGGATCGCTTCT 120
 GAGGTGCTCAAGGAGGAACACAGAGTCTGTGTGGGGTCCCGAGGCTGATGGCA 120
 GAGATGCTCAAGGAGGACACAGAGTGGCTGGGGTCCCGAGCTCCAGCCCTCAGCCCC 117
 HUMAN_IFITM3 GAGATGCTCAAGGAGGACACAGAGTGGCTGTGGGGGCCCCACAACTCGTCTCC 120

ACCCGAGCAGCGGTGGTACGGTG-----GAGAGCCCTGCTGCCTCTCCCGCGAC 132
 GTCAGAACTACTGTGATCAACATGCGCAGAGAGTGTCCGGT-----CTGAC 168
 GCGAGGACGACGGTGGTCAACATCCAGACTGACACAGTGGT-----CCGAC 168
 GTGGCCACACGGTGTCAACATCCAGAGCAGACTCCGTG-----CCGAC 165
 HUMAN_IFITM3 CCGAGCTCCACGTGATCCACATCCGAGCAGACTCCGTG-----CCGAC 168

CACCTGGCCTGTGCTGTGCACACGCTGTACGCCAACGCTGTGCTGCCTGGCTTCTG 192
 CATGTGCTGTGCTGCTGTCACTACTTCTATGAACTTGTGCTGCCTGGCTCTATA 228
 CACTGCTGTGCTGCTGCTGTCAACACCTCTCTCTCAACCCCTGTGCTGCCTGGCT 228
 CACGTGCTGTGCTGCTGCTGTCAACACCTCTCTCACTGAACTGGTGTGCTGCCTGG 225
 HUMAN_IFITM3 CATGTGCTGTGCTGCTGCTGTCAACACCTCTCTCACTGAACTGGTGTGCTGCCT 228

Intron

```

CHICKEN_IFITM3 GCGCTGCTTCTCCGTGAAGgttggggaat...gtctcccagTCCAGGATCGCAAGT 230
MOUSE_IFITM3   GCTATGCTACTCCGTGAAGgtggtgagc...ctgctccagTCTAGGATCGGAAGT 266
MICROBAT_IFITM3 GCGTTCGCTACTCCGTGAAGgtgggtgagc...tctcccagTCTAGGATCGGAAGT 266
PIG_IFITM3     GCTTTCGCTACTCCGTGAAGgtgggtgagc...tctcccagTCCAGGATCGGAAGT 263
HUMAN_IFITM3   GCATTGCTACTCCGTGAAGgtggttatgg...tctcccagTCTAGGATCGGAAGT 266

```

Exon 2

```

CHICKEN_IFITM3 CCTGGTGACTACAGCGGGCGCTCAGCTATGGTCCACTGCGAAGTACCTGAACATC 290
MOUSE_IFITM3   GGTGGGTGATGACTGGAGGCCAGGCTACGCTCCACTGCTAAGTGCCTGAACATC 326
MICROBAT_IFITM3 GTGGGAGACGTGATTTGGGCCAGAGCTATGCTCCACGCCAAGTGCCTGAACATC 326
PIG_IFITM3     GTGGGAGACGTGATTTGGGCCAGAGCTATGCTCCACTGCTAAGTGCCTGAACATC 323
HUMAN_IFITM3   GGTGGGAGCTGACCGGGCCAGGCTATGCTCCACGCCAAGTGCCTGAACATC 326

```

GCCTTCTGATCAACGCTCTCTCATCATCTCATCATGCCCTGGTTGCCAGTGGC 350
 CACCTTGGCTCTCAGCATCTGATGGTGTATCACCATTGTTAGTGT----- 375
 HUMAN_IFITM3 GCCTTCTGATCAACGCTCTCTCATCATCTCATCATGCCCTGGTTGCCAGTGGC 350

CATCATGTTGGCCAACTCTCAACCACAGCAGCAACACCCGAATTCATTGGACCC 410
 -ATCATCATGTTCTTAACGCTCAAACTCTCACACTAA----- 414
 HUMAN_IFITM3 CTTGATGTTTACACCTCTGCACTGAAT-----CGCGGTACGTTGCTTCTATC 428
 CTTGATGTTTCAACGCTCTGCACTGAATCAAAAGGATACAGAGGCTACTAG----- 438
 HUMAN_IFITM3 -GTGCTGATCTTCAGGCTATGGATAG----- 402

CHICKEN_IFITM3 TTAG----- 414
 MOUSE_IFITM3 -----
 MICROBAT_IFITM3 GCCCAAGCTGA 441
 PIG_IFITM3 -----
 HUMAN_IFITM3 -----

(b)

```

HUMAN_IFITM1 -----MHKEHEVAVLGPPPSTILPRSTVINIHSETSV---PDHV 37
HUMAN_IFITM2  MNHVVQT-FSPVNSGPPNVEMLRKEEHEVAVLGVPHPAPPMSSTVIHIRSETSV---PDHV 57
CHICKEN_IFITM3 -----MRRVRSAGSPVPP-YEPLMDGMD--MEGK-----TRSTVVTV--ETPLVPPRDHL 46
CHIMPANZEE_IFITM3 MNHTVQTFPSPVNSGPPNVEMLRKEEHEVAVLGAPHPAPPMSSTVIHIRSETSV---PDHV 58
MOUSE_IFITM3  MNHTSQAFITAAAGGQPPNVERIKEEYEVAEMGAPHGASAVRTVINPREVSV---PDHV 58
MICROBAT_IFITM3 MNPNSQPPFSGARAGVSPSEVLEKEHEVSVLGGPOSSMAARTVVNIQDITVV---PDHI 58
PIG_IFITM3    MNCASQPPFTGAGHG--PPTVEMLRKEEHEVAVLGAPQTSAPVATVINIRSETSV---PDHV 57
HUMAN_IFITM3  MNHVVQTFPSPVNSGPPNVEMLRKEEHEVAVLGAPHPAPPMSSTVIHIRSETSV---PDHV 58

```

N-terminus

```

HUMAN_IFITM1  VWSLFNLFNLNWCCLGIAAYSVNSDRRMVGDVTGAQAYASTAKCLNIWALILGILMT 97
HUMAN_IFITM2  VWSLFNLFMNTCCCLGIAAYSVNSDRRMVGDVTGAQAYASTAKCLNIWALILGIFMT 117
CHICKEN_IFITM3 AWSLCTFLYANVCCCLGLALVFSVNSDRRMVLDGYSGALSYGSTAKYLNITAHLINVFLI 106
CHIMPANZEE_IFITM3 VWSLFNLFMNPCCCLGIAAYSVNSDRRMVGDVTGAQAYASTAKCLNIWALILGILMT 118
MOUSE_IFITM3  VWSLFNLFMNPCCCLGIAAYSVNSDRRMVGDVTGAQAYASTAKCLNISTLVLSILMV 118
MICROBAT_IFITM3 VWSLFNLFMNPCCCLGIAAYSVNSDRRMVGDVIQAQSYASTAKCLNIWAVVLGLLVI 118
PIG_IFITM3    VWSLFNLFMNPCCCLGIAAYSVNSDRRMVGDIIQAQSYASTAKCLNIWALVGLLLI 117
HUMAN_IFITM3  VWSLFNLFMNPCCCLGIAAYSVNSDRRMVGDVTGAQAYASTAKCLNIWALILGILMT 118

```

IM1 CIL IM2
 CD225 domain

```

HUMAN_IFITM1  IGFILLLVFGSVTVYHIMLQIQEKRGY----- 125
HUMAN_IFITM2  ILLIIIP---VLVVQAQR----- 132
CHICKEN_IFITM3 ILIIALVASGTMVAMFNHQQHPFFIGPT--- 137
CHIMPANZEE_IFITM3 ILLIVIP---VLIFQAYG----- 133
MOUSE_IFITM3  VITIVSV---IIVLNAQNLHT----- 137
MICROBAT_IFITM3 VAVIIAV---VVFYTSALN--RGYVGSYHLPQD 146
PIG_IFITM3    IAFIIVCTGSLVIFQAVLQIKDYRGY----- 145
HUMAN_IFITM3  ILLIVIP---VLIFQAYG----- 133

```

C-terminus

Figure 2

[Click here to download high resolution image](#)




Figure3

[Click here to download high resolution image](#)




Figure4

[Click here to download Figure: Figure4.pdf](#)





Figure5

[Click here to download Figure: FIGURE5.pdf](#)







Figure6

[Click here to download Figure: Figure6.pdf](#)







Supplementary Material Files

[Click here to download Supplementary Material Files: Supplementary data.pdf](#)